TY  - JOUR
AU  - Frisoni, Giovanni B
AU  - Hansson, Oskar
AU  - Nichols, Emma
AU  - Garibotto, Valentina
AU  - Schindler, Suzanne E
AU  - van der Flier, Wiesje M
AU  - Jessen, Frank
AU  - Villain, Nicolas
AU  - Arenaza-Urquijo, Eider M
AU  - Crivelli, Lucia
AU  - Fortea, Juan
AU  - Grinberg, Lea T
AU  - Ismail, Zahinoor
AU  - Minoshima, Satoshi
AU  - Ossenkoppele, Rik
AU  - Zetterberg, Henrik
AU  - Petersen, Ronald C
AU  - Dubois, Bruno
TI  - New landscape of the diagnosis of Alzheimer's disease.
JO  - The lancet
VL  - 406
IS  - 10510
SN  - 0140-6736
CY  - London [u.a.]
PB  - Elsevier
M1  - DZNE-2025-01131
SP  - 1389 - 1407
PY  - 2025
AB  - Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide.
KW  - Humans
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Biomarkers: cerebrospinal fluid
KW  - Biomarkers: blood
KW  - Amyloid beta-Peptides: metabolism
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - tau Proteins: cerebrospinal fluid
KW  - tau Proteins: metabolism
KW  - Diagnosis, Differential
KW  - Positron-Emission Tomography
KW  - Biomarkers (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40997838
DO  - DOI:10.1016/S0140-6736(25)01294-2
UR  - https://pub.dzne.de/record/281510
ER  -